Humanized GPC3 Antibody High Affinity Binding

The patent applies parameter changes by modifying the antibody's binding characteristics through humanization processes. The antibody sequence is optimized to achieve higher affinity binding to GPC3, with specific focus on improving the complementarity determining regions (CDRs) while maintaining human framework regions. This results in an antibody with enhanced binding parameters that can more effectively engage GPC3-positive tumor cells, thereby improving clinical effectiveness and anti-tumor effects compared to the original codrituzumab.

The patent achieves improved anti-tumor effects without requiring high doses by changing the binding affinity parameter of the antibody. The humanized antibody design with optimized CDRs and framework regions creates a more potent antibody that can achieve therapeutic efficacy at lower doses, thereby avoiding the immune tolerance and safety issues associated with high-dose administration of the original codrituzumab.

The patent applies universality by designing an antibody with broad binding capability that can effectively engage GPC3 across different tumor types and expression levels. The humanized antibody structure enables it to bind to GPC3-positive cells in a wide range of cancers, making the treatment applicable to a broader patient population without requiring complex selection criteria based on GPC3 expression levels, thereby simplifying the treatment process while maintaining high treatment response rates.